Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II–IIIc breast cancer

[1]  J. Jassem,et al.  Cellular Redox Pathways as a Therapeutic Target in the Treatment of Cancer , 2011, Drugs.

[2]  C. Perou,et al.  TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab , 2012, Breast Cancer Research and Treatment.

[3]  C. Glorieux,et al.  Catalase overexpression in mammary cancer cells leads to a less aggressive phenotype and an altered response to chemotherapy. , 2011, Biochemical pharmacology.

[4]  A. Rosato,et al.  A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. , 2011, Blood.

[5]  F. Chang,et al.  Selective targeting of breast cancer cells through ROS-mediated mechanisms potentiates the lethality of paclitaxel by a novel diterpene, gelomulide K. , 2011, Free radical biology & medicine.

[6]  D. Townsend,et al.  The role of glutathione S-transferase P in signaling pathways and S-glutathionylation in cancer. , 2011, Free radical biology & medicine.

[7]  D. Stocken,et al.  Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13 , 2011, Cancer Immunology, Immunotherapy.

[8]  G. Wondrak,et al.  DCPIP (2,6-dichlorophenolindophenol) as a genotype-directed redox chemotherapeutic targeting NQO1*2 breast carcinoma , 2011, Free radical research.

[9]  M. Fishman,et al.  Changes in Dendritic Cell Phenotype After a New High-dose Weekly Schedule of Interleukin-2 Therapy for Kidney Cancer and Melanoma , 2010, Journal of immunotherapy.

[10]  S. Ostrand-Rosenberg.  Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity , 2010, Cancer Immunology, Immunotherapy.

[11]  D. Townsend,et al.  Abstract 1615: The redox modulator NOV-002 inhibits proliferation of ovarian tumor cells but increases proliferation of myeloid cells , 2010 .

[12]  S. Rodenhuis,et al.  The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy , 2010, Annals of Surgical Oncology.

[13]  Min Xu,et al.  Abstract C238: Nov‐002, a cellular redox modulator, enhances the antitumor effect of adoptively transferred T cells in a murine melanoma model , 2009 .

[14]  D. Townsend,et al.  Abstract C109: NOV‐002 suppresses tumor cell growth by modulating redox‐sensitive cell signaling , 2009 .

[15]  G. Wondrak.  Redox-directed cancer therapeutics: molecular mechanisms and opportunities. , 2009, Antioxidants & redox signaling.

[16]  S. Mocellin,et al.  IL4Rα+ Myeloid-Derived Suppressor Cell Expansion in Cancer Patients1 , 2009, The Journal of Immunology.

[17]  D. Townsend,et al.  Pharmacology of a mimetic of glutathione disulfide, NOV-002. , 2009, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[18]  D. Hunter,et al.  A prospective study of genetic polymorphism in MPO, antioxidant status, and breast cancer risk , 2009, Breast Cancer Research and Treatment.

[19]  S. Glück,et al.  XeNA: Capecitabine Plus Docetaxel, With or Without Trastuzumab, as Preoperative Therapy for Early Breast Cancer , 2008, International journal of medical sciences.

[20]  L. Zitvogel,et al.  Immunogenic cancer cell death: a key-lock paradigm. , 2008, Current opinion in immunology.

[21]  M. Sattler,et al.  Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications. , 2008, Antioxidants & redox signaling.

[22]  Peng Huang,et al.  Redox regulation of cell survival. , 2008, Antioxidants & redox signaling.

[23]  E. Winer,et al.  Lymphopenia associated with adjuvant anthracycline/ taxane regimens. , 2008, Clinical breast cancer.

[24]  Tatsuki Koyama,et al.  Proper inference from Simon's two‐stage designs , 2008, Statistics in medicine.

[25]  D. Townsend,et al.  NOV-002, a mimetic of glutathione disulfide , 2008, Expert opinion on investigational drugs.

[26]  U. Matulonis,et al.  NOV-002 plus carboplatin in platinum-resistant ovarian cancer , 2008 .

[27]  D. Townsend,et al.  NOV-002, a glutathione disulfide mimetic, as a modulator of cellular redox balance. , 2008, Cancer research.

[28]  M. Nishimura,et al.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy , 2008, Cancer Immunology, Immunotherapy.

[29]  D. Townsend,et al.  S-glutathionylation: indicator of cell stress and regulator of the unfolded protein response. , 2007, Molecular interventions.

[30]  Christos Hatzis,et al.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  K. Hess,et al.  Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  L. Zitvogel,et al.  Calreticulin exposure dictates the immunogenicity of cancer cell death , 2007, Nature Medicine.

[33]  G. Giles.  The redox regulation of thiol dependent signaling pathways in cancer. , 2006, Current pharmaceutical design.

[34]  R. Brigelius-Flohé,et al.  Glutathione peroxidases and redox-regulated transcription factors , 2006, Biological chemistry.

[35]  Jinsong Liu,et al.  Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. , 2006, Cancer cell.

[36]  H. Gerstein,et al.  NOV-002, a chemoprotectant/immunomodulator, added to first-line carboplatin/paclitaxel in advanced non-small cell lung cancer (NSCLC): A randomized Phase 1/2, open-label, controlled study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Norman Wolmark,et al.  Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  G. Hortobagyi,et al.  Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  H. Tsuda,et al.  Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer , 2006, Breast cancer.

[40]  G. Hortobagyi,et al.  Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  L. Carey,et al.  American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. , 2005, Journal of the National Cancer Institute.

[42]  J. Blohmer,et al.  Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  G. Hortobagyi,et al.  Docetaxel for treatment of solid tumours: a systematic review of clinical data. , 2005, The Lancet. Oncology.

[44]  Olivier Soubrane,et al.  Controlling tumor growth by modulating endogenous production of reactive oxygen species. , 2005, Cancer research.

[45]  A. Hutcheon,et al.  Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival , 2005, Breast Cancer Research and Treatment.

[46]  J. Stec,et al.  Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  D. Wickerham,et al.  The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  J. Bryant,et al.  Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. , 2001, Journal of the National Cancer Institute. Monographs.

[49]  K. Tew,et al.  Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways. , 2001, The Journal of pharmacology and experimental therapeutics.

[50]  Anna L. Brown,et al.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  J. Zweier,et al.  Mitogenic Signaling Mediated by Oxidants in Ras-Transformed Fibroblasts , 1997, Science.

[52]  W. Willett,et al.  Breast cancer (1) , 1992, The New England journal of medicine.